🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Enriqueta Felip

Hebron University

ORCID: 0000-0002-7620-0098

Also affiliated with Institut Català d'Ornitologia, Vall d'Hebron Institut de Recerca, Institut Català d'Oncologia, Vall d'Hebron Hospital Universitari, Badalona Serveis Assistencials, Hospital Municipal de Badalona, Vall d'Hebron Institute of Oncology

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial”.

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00064-0

N/A

3.7DataRank · unranked

164 citations

Enriqueta Felip, Dipesh Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz‐Ares +15 more

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

New England Journal of Medicine(2015)10.1056/nejmoa1507643

N/A

1.4DataRank · unranked

9414 citations

Luis Paz-Ares, Diane P Holder, David R. Spigel, Martin Steins, Neal E. Ready +38 more

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

New England Journal of Medicine(2018)10.1056/nejmoa1801005

N/A

1.3DataRank · unranked

6524 citations

Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis +34 more

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

The Lancet(2016)10.1016/s0140-6736(15)01281-7

N/A

1.3DataRank · unranked

6497 citations

Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han +20 more

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy

Annals of Oncology(2011)10.1093/annonc/mdr150

N/A

0.695DataRank · unranked

102 citations

C. Gridelli, R. Rosell, R. Stahel, Enriqueta Felip, Cesare Gridelli +3 more

Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1591

N/A

0.292DataRank · unranked

6 citations

Gilberto Lopes, T. Jeroen N. Hiltermann, Ramaswamy Govindan, Liza C. Villaruz, Emiliano Calvo +19 more

LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression

Annals of Oncology(2023)10.1016/j.annonc.2023.10.053

N/A

0DataRank · unranked

19 citations

Patrick M. Forde, J.D. Spicer, C. Wang, Shun Lu, Tetsuya Mitsudomi +15 more

970TiP SKYSCRAPER-05: Phase II study of neoadjuvant atezolizumab (Atezo) + tiragolumab (Tira) with or without platinum-based chemotherapy (CT) in patients (Pts) with locally advanced resectable stage II‒IIIB NSCLC

Annals of Oncology(2022)10.1016/j.annonc.2022.07.1096

N/A

0DataRank · unranked

5 citations

A.W. Kim, Enriqueta Felip, Catherine A. Shu, Andrea Ferris, M. Frueh +8 more

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0231

N/A

0DataRank · unranked

49 citations

Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson +23 more

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.03.003

N/A

0DataRank · unranked

222 citations

Tae Min Kim, David Vicente, Enriqueta Felip, Dae Ho Lee, Ki Hyeong Lee +10 more